The TLR3‐agonist poly(I:C) has been developed to simulate pathogen infection and promote immune system activation to enhance anticancer therapy and has shown significant therapeutic effects in preclinical models of melanoma, kidney cancer, and colorectal cancer.52, 53, 54. Here, TLR3 is linked to melanoma.